The data are based on a survey conducted during the 2nd quarter of 2015. It describes major advantages of developing personalized medicines according to pharmaceutical companies in Asia, Europe, and in the U.S. Some 26% of respondents stated that the likelihood of a higher drug price tag would be a major advantage of personalized medicines.
Higher drug price tag likely | 26 |
Better efficacy rate per patient, lesser likelihood of non-responders | 25 |
Better cost/bene fit argument at payer level | 24 |
More targeted treatment raises potential for disease modification | 16 |
Smaller clinical trials | 9 |